Lenz Brian's most recent trade in Adma Biologics Inc was a trade of 16,965 Common Stock done at an average price of $6.2 . Disclosure was reported to the exchange on March 6, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.16 per share. | 06 Mar 2024 | 16,965 | 703,002 (0%) | 0% | 6.2 | 104,504 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 06 Mar 2024 | 16,677 | 719,967 (0%) | 0% | 6.1 | 102,063 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.36 per share. | 29 Feb 2024 | 4,935 | 736,644 (0%) | 0% | 5.4 | 26,452 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.26 per share. | 25 Feb 2024 | 8,257 | 741,579 (0%) | 0% | 5.3 | 43,432 | Common Stock |
| Adma Biologics Inc | Lenz Brian | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.52 per share. | 31 Dec 2023 | 16,908 | 749,836 (0%) | 0% | 4.5 | 76,424 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.61 per share. | 15 Aug 2023 | 631,078 | 960,197 (1%) | 0% | 4.6 | 2,909,270 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Sale of securities on an exchange or to another person at price $ 4.60 per share. | 15 Aug 2023 | 211,578 | 782,013 (0%) | 0% | 4.6 | 972,730 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 15 Aug 2023 | 200,000 | 1,248,803 (1%) | 0% | 3.2 | 644,000 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 192,472 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. | 15 Aug 2023 | 192,472 | 1,591,275 (1%) | 0% | 3.7 | 704,448 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 15 Aug 2023 | 178,184 | 782,013 (0%) | 0% | 4.5 | 793,400 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.71 per share. | 15 Aug 2023 | 150,000 | 1,398,803 (1%) | 0% | 3.7 | 556,500 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 97,395 | 177,605 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share. | 15 Aug 2023 | 97,395 | 879,408 (1%) | 0% | 1.7 | 162,650 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 85,416 | 14,584 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.92 per share. | 15 Aug 2023 | 85,416 | 1,048,803 (1%) | 0% | 2.9 | 249,415 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 83,979 | 55,021 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.35 per share. | 15 Aug 2023 | 83,979 | 963,387 (1%) | 0% | 2.4 | 197,351 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.69 per share. | 30 Jun 2023 | 15,268 | 993,591 (1%) | 0% | 3.7 | 56,339 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.31 per share. | 31 Mar 2023 | 15,469 | 1,008,858 (1%) | 0% | 3.3 | 51,202 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 270,345 | 270,345 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 135,175 | 1,041,292 (1%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 25 Feb 2023 | 16,965 | 1,024,327 (1%) | 0% | 3.4 | 57,681 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 25 Feb 2023 | 7,927 | 911,117 (1%) | 0% | 3.4 | 27,110 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 25 Feb 2023 | 5,000 | 906,117 (1%) | 0% | 3.6 | 17,750 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 25 Feb 2023 | 1,559 | 919,044 (1%) | 0% | 3.4 | 5,332 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.87 per share. | 04 Jan 2023 | 114,222 | 920,603 (1%) | 0% | 3.9 | 442,039 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.43 per share. | 30 Sep 2022 | 73,678 | 1,027,832 (1%) | 0% | 2.4 | 179,038 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.46 per share. | 23 Mar 2022 | 37,178 | 1,153,475 (1%) | 0% | 1.5 | 54,280 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 275,000 | 275,000 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 137,500 | 1,190,653 (1%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 25 Oct 2021 | 30,000 | 1,065,501 (1%) | 0% | 1 | 30,000 | Common Stock |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 139,000 | 139,000 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 63,936 | 140,078 (0%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Brian Lenz | EVP, CFO | Purchase of securities on an exchange or from another person at price $ 2.96 per share. | 11 Aug 2020 | 4,000 | 76,142 (0%) | 0% | 3.0 | 11,860 | Common Stock |